Motivational Interviewing (MI) has been described as a collaborative, goal orientated style of communication with particular attention to the language of change. The presentation will consider a contemporary perspective of MI including both its relational and technical components as well as its role in eliciting and strengthening change talk and managing patient resistance toward change. It will consider the issues of behaviour change and propose a values matching approach toward long-term behaviour change using MI as an integrative therapy. Many clinical trials have reported the use of MI across a range of settings although, as the presentation will highlight, it is often not clear whether the intervention was delivered as intended. Dr Breckon will consider the role of treatment fidelity frameworks as an essential facet of health behaviour change interventions such as MI to ensure greater consistency and replicability of counselling approaches. Disclosure statement: The author has declared no conflicts of interest.
Motivational Interviewing (MI) has been described as a collaborative, goal orientated style of communication with particular attention to the language of change. The presentation will consider a contemporary perspective of MI including both its relational and technical components as well as its role in eliciting and strengthening change talk and managing patient resistance toward change. It will consider the issues of behaviour change and propose a values matching approach toward long-term behaviour change using MI as an integrative therapy. Many clinical trials have reported the use of MI across a range of settings although, as the presentation will highlight, it is often not clear whether the intervention was delivered as intended. Dr Breckon will consider the role of treatment fidelity frameworks as an essential facet of health behaviour change interventions such as MI to ensure greater consistency and replicability of counselling approaches. Disclosure statement: The author has declared no conflicts of interest. Evidence has shown that nurse-led care is a cost effective way of ensuring people with inflammatory arthritis have the right care at the right time in the right place. There are always challenges when implementing new initiatives or making changes and this presentation will provide some practical solutions to setting up nurse-led care including the importance of ensuring quality of care and undertaking audit. There will be an opportunity for discussion and this will be an interactive session. Disclosure statement: The author has declared no conflicts of interest. It is well known that persons with inflammatory arthritis have an increased morbidity and mortality compared with the general population due to comorbidities such as cardiovascular disease (CVD). In 2010 EULAR recommendations for cardio vascular risk management in persons with inflammatory arthritis was published. Cardiovascular risk assessment in all patients with RA was recommended. Any identified risks should be managed according to local guidelines. The lecture will provide an overview of how we set out to implement these recommendations at a Danish hospital in the form of planned nurseled consultations. The lecture will include information about the specific content and documentation of the nurse consultations including an estimation of the patients' 10 year risk for cardiovascular death using the European SCORE system. The results regarding the spread of the different risk factors and risk scores in a RA population will be provided in short and opportunities for future development and research will be discussed. Disclosure statement: The author has declared no conflicts of interest.
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I97. NURSE-LED SCREENING FOR CARDIOVASCULAR RISK IN RA AND OTHER TYPES OF INFLAMMATORY ARTHRITIS: EXPERIENCE FROM DENMARK
I98. NURSE-LED CARE: IS THE FUTURE ORANGE? USING THE EVIDENCE TO MAXIMIZE THE EFFECTS
Mwidimi Ndosi Nurse-led care (NLC) can be described as having the following characteristics: providing patients with a direct access to care, assessment of a person's physical, mental and emotional health, ability to discriminate between normal and abnormal findings, referral to other members of the multidisciplinary team or a physician, health promotion and preventative health care, prescribing and carrying out appropriate treatments. This model of care has been used successfully in other chronic diseases such as diabetes, coronary heart diseases and chronic obstructive pulmonary disease, where patients require regular follow-ups and monitoring. In rheumatology, NLC evolution over the last two decades has been driven by patients' changing needs and professional development within nursing and there is growing evidence that this model of care is both effective and associated with lower healthcare costs. Given the developments in the care of people with arthritis, such as early aggressive treatment in early arthritis and prevention of comorbidities in established disease, NLC needs to continue to evolve to ensure that patients' needs are met effectively. Since NLC is a complex intervention and it is integrated within evolving healthcare systems, assessing its effectiveness can be challenging. The current and future ambitions need to take account of the changing patients' needs and outcomes, the evolving healthcare system and healthcare costs. This lecture attempts to look into the evidence and explore the opportunities for maximizing the effects of NLC in rheumatology. Currently patients are classified according to the extent of skin disease into diffuse or limited cases although long term outcome deepens more upon the presence of internal organ complications that can occur in either subset. Cases of lung fibrosis, pulmonary hypertension, gastrointestinal tract disease and scleroderma renal crisis will be discussed and current best practice management of these specific aspects of the disease together with more general strategies for assessment, screening and risk stratification of SSc will be discussed. Disclosure statement: C.D. has served as a consultant for Actelion, GSK, Roche and Pfizer; has received honoraria from Actelion, GSK, Roche and Pfizer; and has received grants/research support from Actelion.
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